SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

SAB Biotherapeutics has announced first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza. (Credit: Steve Buissinne from Pixabay)